Eidos Therapeutics, Inc
We are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.
$15.00 - $17.00
J.P. Morgan, BofA Merrill Lynch, Barclays
To view the prospectus for Eidos Therapeutics, Inc IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253